---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-008264"
form_type: "8-K"
ticker: "ENVB"
cik: "0000890821"
company_name: "Enveric Biosciences, Inc."
filed_at: "2024-02-29T23:59:59+00:00"
generated_at: "2026-06-05T07:43:28.685501+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Enveric signs non-binding term sheets to out-license three compound classes; potential $200M milestones

## Summary
- Three non-binding term sheets signed with undisclosed biotech for exclusive global out-licenses of three compound classes.
- Potential total milestone payments and execution fees up to $200M if all development and sales criteria are met.
- Royalty rates on each license range from 2.5% to 10% on future sales depending on criteria.
- Compounds from Enveric's Psybrary platform library of over 1,000 novel molecules generated using AI drug discovery.
- Licensee assumes all future preclinical and clinical development costs for human/animal applications.

## SEC filing metadata
- accession: 0001493152-24-008264
- form_type: 8-K
- ticker: ENVB
- cik: 0000890821
- company_name: Enveric Biosciences, Inc.
- filed_at: 2024-02-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/890821/000149315224008264/0001493152-24-008264-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/890821/000149315224008264/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-008264
- JSON: https://secwatch.observer/filing/0001493152-24-008264.json
- Plain text: https://secwatch.observer/filing/0001493152-24-008264.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.